PTC Therapeutics Inc
XMUN:BH3
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of
PTC Therapeutics Inc (BH3) under the Base Case is 75.35 EUR per share.
Compared with the current market price of 56.2 EUR, the stock appears
Undervalued by 25% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What PTC Therapeutics Does
PTC Therapeutics is a biotechnology company that focuses on medicines for rare diseases, especially inherited disorders that affect children and small patient groups. It develops drugs meant to treat the root cause of certain genetic conditions, then seeks approval to sell them in the United States and other markets. Its business is narrower than a big drugmaker’s: it concentrates on hard-to-treat diseases where patients have few other options.
- Headquarters
- United States of America US
- Employees
- 991
- IPO date
- Jun 20, 2013
PTC Therapeutics has a narrow economic moat
PTC Therapeutics Inc has a narrow economic moat, offering limited protection against competitors and some ability to sustain profitability.
Read the full moat analysisBalance Sheet
Recent Events
Latest Earnings Call
Sephience’s launch momentum supported a higher 2026 outlook, while the ST-920 acquisition added a near-term Fabry gene-therapy opportunity.
Open the earnings call- EPS
- $0.61
- Expected
- $0.17
- Surprise
- +258.8%
- Stock, next trading day
- −7.0%
PTC Therapeutics insiders are selling more than usual
Insiders sell for many reasons, such as taxes or planned sales; purchases are rarer.
Past 12 months
Continue BH3 Research
Decided on PTC Therapeutics? Get an email when BH3 reaches the price you’d buy at. Free with an account.
Other PTC Therapeutics listings
What is the Intrinsic Value of one BH3 stock?
The intrinsic value for
PTC Therapeutics Inc (BH3) under the Base Case is 75.35 EUR.
Is BH3 stock undervalued or overvalued?
Compared with the current market price of 56.2 EUR, the stock appears Undervalued by 25% .